Skip to content
‹ Back to IndustriesSciences

China Is Showing No Signs of Slowing Down Space Exploration

Blaine Curcio is the Founder of Orbital Gateway Consulting and a foremost expert on the Chinese space sector. His podcast, Dongfang Hour, provides essential information on the Chinese space program from Chinese sources. Space to Grow’s Chris Blackerby and Charity Weeden recently got the opportunity to chat with Blaine and talk about all things…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Chris Blackerby · · Blaine CurcioChina Space ProgramDongfang HourSpace Economy
Share

Key takeaways

01

Blaine Curcio is the Founder of Orbital Gateway Consulting and a foremost expert on the Chinese space sector.

02

His podcast, Dongfang Hour, provides essential information on the Chinese space program from Chinese sources.

03

Space to Grow’s Chris Blackerby and Charity Weeden recently got the opportunity to chat with Blaine and talk about all things…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Blaine Curcio is the Founder of Orbital Gateway Consulting and a foremost expert on the Chinese space sector. His podcast, Dongfang Hour, provides essential information on the Chinese space program from Chinese sources. Space to Grow’s Chris Blackerby and Charity Weeden recently got the opportunity to chat with Blaine and talk about all things space exploration in China.

Is the Chinese space program shrouded in mystery, or is this a perception issue in the West? Weeden wanted to know the facts from the cloud of misinformation.

“One thing I hear a lot is this assumption that the Chinese government is omnipotent,” Curcio said. “If they say, for example, build us a 5,000 satellite LEO broadband constellation, there’s an impression that will just get done tomorrow, and there are no questions asked; at the end of the day, that’s an oversimplification in the sense that you do have in this system a lot of different competing forces, factions, and entities that have their own interests. And you have incentives that don’t make it that easy.”

For the past decade, China’s made a significant investment in space, technology, resources, and funding. And they show no signs of slowing down with ambitious plans over the next several years. They plan to complete the International Lunar Research Station in the next fifteen years. “If we look at plans like that, that seems extremely ambitious,” Curcio said. “And I think the space station has some interesting potential to expand in the medium to long-term.”

One difference between the Chinese space program and The United States is the coordination of efforts. The US tends to lead national efforts run by NASA, and China takes a more siloed approach with various companies working with local and provincial governments. Without a top-down coordinated attempt, Curcio said some of China’s plans for space could experience difficulties.

More in This Series

The Infrastructure Available to the Commercial Space Industry will Impact Affordability of Launches

The Impact of the Russian ASAT Tests

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

CB
Chris Blackerby
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Agilent's new 5987A GC/MS takes aim at costly sample reruns

Agilent's new 5987A GC/MS takes aim at costly sample reruns

Agilent’s 5987A GC/MSD adds vendor-claimed up to 25% faster scanning and a wider detector range alongside GC Assist diagnostics tracking 60-plus parameters. Its design focuses on taking injections out of workflows to limit reruns. With helium spot prices reportedly doubling after the March 2026 disruption, avoided reruns can save gas, but EPA criteria checks and ISO/IEC 17025 verification still come first.

  • 01Injection-cutting features can matter most: MassHunter’s simultaneous dSIM/Scan to combine SIM quantitation and library-searchable full scan in one run, and Agilent’s claim of an order-of-magnitude wider dynamic range that could reduce dilution reinjections if it holds up in routine use.
  • 02Onboard diagnostics pay back unevenly. Labs that find faults by failing QC batches stand to gain the most, while labs on comprehensive service contracts may mainly change which contract tier they buy.
  • 03The up-to-40% energy cut applies with the IDP-4 pump, so bid scoring should confirm the quoted configuration before crediting the savings.

Nov 10, 2026

Adding Genmab's petosemtamab to Keytruda cut head and neck cancer death risk in half

Adding Genmab's petosemtamab to Keytruda cut head and neck cancer death risk in half

Genmab's petosemtamab, added to Merck's Keytruda, cut the risk of death by 50% in 699 first-line head and neck cancer patients. The trial held regardless of HPV status. Full data will be presented at an upcoming medical meeting.

  • 01In a cancer where median survival runs about 10 to 12 months, adding petosemtamab to Keytruda halved the risk of death at the first interim look.
  • 02The benefit held regardless of HPV status, supporting use in PD-L1-positive patients without separating by HPV status.
  • 03The figure to watch at the full-data presentation is median overall survival in each arm, because the topline release reports only the hazard ratio.

Nov 9, 2026

UCB commits to Veeva Vault CRM platform

UCB commits to Veeva Vault CRM platform

UCB has committed to Veeva Vault CRM, which Veeva’s release presents as an agentic CRM platform to drive unified engagement worldwide. UCB and Veeva executives describe it as a stable foundation for UCB’s commercial strategy, while the AI claims, including the Agentic Call Report, come from Veeva’s product description. No go-live date or financial terms were given.

  • 01The executive statements focus on Vault CRM as a foundation. The AI pitch, including the Agentic Call Report, comes from Veeva’s product description.
  • 02Veeva says the Agentic Call Report turns field call records into "Commercial Evidence" about treatment barriers that went unseen before. If it works as described, call reports gain value when analyzed at scale.
  • 03No go-live date or financial terms were disclosed. A go-live date or first-market rollout from UCB would show whether a worldwide migration is moving.

Nov 7, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

CB
Chris Blackerby

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512